# Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

> **NCT02870244** · PHASE1 · RECRUITING · sponsor: **Loyola University** · enrollment: 18 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Escalating Doses

## Key facts

- **NCT ID:** NCT02870244
- **Lead sponsor:** Loyola University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-02
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02870244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02870244, "Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02870244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*